SCM
TSHA icon

Sterling Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

Sterling Capital Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.73K Sell
842
-569
-40% -$3.37K ﹤0.01% 2537
2026
Q1 		$6.31K Hold
1,411
– – ﹤0.01% 2618
2025
Q4 		$7.76K Buy
1,411
+896
+174% +$4.35K ﹤0.01% 2725
2025
Q3 		$1.68K Buy
515
+107
+26% +$303 ﹤0.01% 3008
2025
Q2 		$942 Buy
408
+243
+147% +$528 ﹤0.01% 3069
2025
Q1 		$229 Hold
165
– – ﹤0.01% 3069
2024
Q4 		$285 Hold
165
– – ﹤0.01% 3085
2024
Q3 		$332 Buy
+165
New +$362 ﹤0.01% 3009

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sterling Capital Management's TSHA Position: Q2 2026 in Review

Sterling Capital Management reduced its Taysha Gene Therapies (TSHA) stake by 40% in Q2 2026, selling an estimated $3.37K and leaving 842 shares worth $5.73K. The position accounts for ﹤0.01% of the portfolio, ranked #2537.

Sterling Capital Management first reported a position in TSHA in Q3 2024 and has held it in 8 quarters since. The position peaked at $7.76K in Q4 2025. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Sterling Capital Management held 842 shares of Taysha Gene Therapies worth $5.73K as of Q2 2026.
  • Sterling Capital Management sold 569 Taysha Gene Therapies shares in Q2 2026, an estimated $3.37K.
  • Taysha Gene Therapies made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2537 holding.
  • Sterling Capital Management first reported a position in Taysha Gene Therapies in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Taysha Gene Therapies position peaked at $7.76K in Q4 2025.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.